Miravo Healthcare™ Announces Second Quarter 2021 Results
– Q2 2021 Adjusted Total Revenue – $19.9 million — Q2 2021 Adjusted EBITDA – $7.4 million — Blexten Canadian Prescriptions Increased 26% Year-Over-Year — Cambia Canadian Prescriptions Increased 17% Year-Over-Year –
Miravo to Host Conference Call/Audio…
